Ronnie Morris, MD, Chief Executive Officer

Ronnie Morris, MD, was most recently one of the founders of MDVIP, the national leader in personalized healthcare. Serving as a board member, medical director and part of the executive management team, Dr. Morris helped build and manage MDVIP, a company that grew to a network of 400 doctors within 29 states servicing 125,000 consumers/patients. In December 2009, MDVIP was acquired by the Procter and Gamble Co. Prior to MDVIP, Dr. Morris was the chief medical officer and executive VP of AllianceCare, a 1500-plus-employee company that provided home healthcare, physical therapy and doctor visits for homebound patients. At AllianceCare, Dr. Morris developed and operated the physician house call division of the business, and he was the general medical director for the company. He was the managing partner of a large multispecialty group that was acquired in 1998 by ProMedCo. Dr. Morris is a board-certified internist and until 2004, he had a private practice in Boca Raton, Florida. He has been a consultant for many pharmaceutical companies, including Pfizer, Merck and AstraZeneca.

Angela M. Davies, MD, FRCP (C), Chief Medical Officer

Angela M. Davies, MD, FRCP(C) joined Champions Oncology in January 2014 as the company’s chief medical officer. Most recently, Dr. Davies served as chief medical officer at Novocure, where she had global responsibility for the organization’s clinical development program and commercial safety. Dr. Davies previously served as chief medical officer at OSI Pharmaceuticals where she led the oncology clinical development program for Tarceva (erlotinib) and the pipeline compounds. Prior to OSI she was associate professor of medicine at University of California, Davis where she practiced as a medical oncologist specializing in thoracic malignancies and development therapeutics. Dr. Davies is a board-certified internist and medical oncologist. She obtained her medical degree and completed her specialty medical training at McMaster University, Hamilton, Canada and University of Toronto, Toronto, Canada.

Philip Breitfeld, MD, Chief Scientific and Innovation Officer

Philip Breitfeld, MD has more than 30 years of experience in oncology and was most recently Global Vice President at Quintiles, responsible for the Therapeutic Centers of Excellence. Prior to that, he led the Oncology Center of Excellence at Quintiles where he worked with many large, mid-size and emerging biopharmaceutical firms. He held senior clinical development positions at Merck KGaA (EMD Serono in the US), where he led oncology development in the US, and at BioCryst, where he led oncology development and was Associate Chief Medical Officer. Prior to his career in industry, he held academic positions at Harvard, University of Massachusetts, Indiana University, and Duke.  He has approximately 50 publications in the literature dealing with basic cell and molecular biology, and translational and clinical oncology. He was trained in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD) from the University of Rochester, and his undergraduate degree (AB in chemistry) from Princeton. Dr. Breitfeld is also a Director on the Company’s Board of Directors.

Jordan Rubinson, MBA, Chief Commercial Officer

Jordan Rubinson has 17 years’ experience in the pharmaceutical industry with Pfizer, GlaxoSmithKline, Aventis and most recently as the CEO of Polyheal Ltd., which is strategically allied with Teva Pharmaceuticals. Immediately prior, Mr. Rubinson worked at Pfizer as the marketing director in Israel, where he launched five new products in three years. Just prior at GSK, Mr. Rubinson worked in U.S. marketing where he managed assets of over $200M in annual sales, brought to market several category-leading vaccines, and earned the company Frost and Sullivan’s Market Engineering Excellence Award. He also worked in GSK France managing a large field force division of over 100 employees. While at Aventis, Mr. Rubinson had assignments in France, Canada and the U.S. in the areas of strategic marketing, manufacturing and sales. Mr. Rubinson holds an engineering degree from Columbia University and an MBA from MIT’s Sloan School of Management.

Neal Goodwin, PhD, Vice President, Corporate Research Development

Neal Goodwin, PhD, serves as vice president, corporate research development for Champions Oncology. His responsibilities include development of the patient-derived TumorGraft pharmacology portfolio for both the Personalized Oncology and Translational Oncology Solutions. He previously served as the director, research and development, and the founding program director of JAX Cancer Services. Dr. Goodwin was the cofounder and chief scientific officer of ProNAi Therapeutics, an advanced clinical trial-staged oncology therapeutics firm. He also previously served as a senior research scientist in genomic technologies at Pharmacia. Dr. Goodwin received a PhD in microbiology from the University of Montana and served a postdoctoral fellowship in functional genomics at The Jackson Laboratory with John Schimenti (now at Cornell).

David Miller, MBA, Vice President, Finance

David Miller serves as the vice president of finance at Champions Oncology, Inc. Mr. Miller served as vice president of finance and Operations at DMCWW, LLC. From January 2006 to March 2010, he served as the chief financial officer of NAF Funding, LLC. From January 2000 to December 2005, he served as vice president of finance and Operations at IDT Corp., where he led the creation and growth of the consumer phone services division to over one million customers of local and long distance service. From 1997 to 1999, he served as an assistant vice president of the internal audit department at Deutche Bank. He also held senior accountant positions at Schonbraun, Safris, Sternlieb, LLC and Margolin, Winer and Evans. He is a Certified Public Accountant. He holds a B.S. from Yeshiva University in 1991 and an MBA from Fordham in 1999.

Maria Mancini, PhD, Vice President, Pharmacology

Maria Mancini, PhD, joined Champions in March of 2015 and serves as Vice President of Pharmacology overseeing the scientific operations of pharmacology research initiatives including  pre-clinical, co-clinical and CLIA approved drug sensitivity testing. She previously served as the Director of Research for Biomodels LLC leading efforts to generate translational in vivo platforms to test the efficacy of agents developed to treat cancer and cancer regimen-related toxicities. Dr. Mancini received her PhD in Biochemistry and Molecular Genetics from the University of Maine and served a Postdoctoral fellowship in Oncology at Harvard Medical School in the laboratory of Dr. Alex Toker.

David DeOrnellis, BS, RLATG, CPIA, CMAR, Vice President, Global Laboratory Operations

David DeOrnellis joined Champions Oncology in June 2015 and serves as Vice President of Global Laboratory Operations, overseeing all aspects of the in vivo program, the Quality Management System, and regulatory compliance.  Mr. DeOrnellis has twenty years of experience in biomedical research.  Most recently, he served as Global Director of Quality Assurance at Harlan Laboratories, where he was responsible for the Quality Management System and Training Program for nineteen sites in eight countries.  Immediately prior, he was the Associate Director of Technical Services at Novartis Institutes for BioMedical Research where he implemented a Technical Services team to provide in vivo study and surgical support, training, and colony management to meet the research needs for two Novartis divisions.  Mr. DeOrnellis holds a BS from Arizona State University and maintains certifications through AALAS, PRIM&R, and ASQ.

Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology